Addition of hormonal therapy to radiotherapy improves overall survival in men with high-risk prostate cancer compared with radiotherapy alone. This effect is explained by mechanisms such as cytoreduction, androgen receptor regulation in key DNA damage response pathways and suppression of micrometastases. However, randomized trials evaluating the benefit of adding hormone therapy to postoperative radiotherapy (PORT) have yielded conflicting results. This commentary focuses on the impact of combination therapy after prostate surgery. Hormonal therapy thus complements radiotherapy in high-risk patients. Studies show different results depending on the type and stage of the disease.